xCT as a Predictor for Survival in a Population-Based Cohort of Head and Neck Squamous Cell Carcinoma

被引:0
|
作者
Nissi, Linda [1 ,2 ,3 ]
Tuominen, Sanni [4 ,5 ]
Routila, Johannes [3 ,6 ]
Huusko, Teemu [3 ,6 ]
Ketonen, Petra [4 ,5 ]
Sundvall, Maria [1 ,2 ,3 ,7 ]
Leivo, Ilmo [3 ,8 ]
Irjala, Heikki [3 ,6 ]
Minn, Heikki [1 ,2 ,3 ]
Gronroos, Tove J. [1 ,4 ,5 ]
Ventela, Sami [6 ,9 ]
机构
[1] Turku Univ Hosp, Dept Oncol, Turku, Finland
[2] Turku Univ Hosp, FICAN West Canc Ctr, Turku, Finland
[3] Univ Turku, Turku, Finland
[4] Univ Turku, Preclin Imaging Turku PET Ctr, Turku, Finland
[5] Univ Turku, Med Res Lab, Turku, Finland
[6] Turku Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland
[7] Univ Turku, Inst Biomed, Canc Res Unit, Turku, Finland
[8] Turku Univ Hosp, Dept Pathol, Turku, Finland
[9] Univ Turku, Turku Biosci Ctr, Turku, Finland
来源
CANCER MEDICINE | 2024年 / 13卷 / 21期
关键词
CYSTEINE/GLUTAMATE TRANSPORTER; CISPLATIN RESISTANCE; CANCER-CELLS; FOLLOW-UP; FERROPTOSIS; BIOMARKER; SLC7A11; SULFASALAZINE; SUPPRESSION; RECURRENCE;
D O I
10.1002/cam4.70371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: xCT, also known as SLC7A11 (solute carrier Family 7 Member 11), is a cystine/glutamate antiporter protein that mediates regulated cell death and antioxidant defense. The aim of this study was to investigate the effect of xCT on the outcome of patients diagnosed with new head and neck squamous cell carcinoma (HNSCC). Methods: This retrospective cohort study utilized a population-based dataset, comprising all patients (n = 1033) diagnosed with new HNSCC during 2005-2015 in a population of 697,000 people. All patients (n = 585) with a tumor tissue sample available for immunohistochemical (IHC) staining were included. The follow-up rates were 97% and 81% at 3 and 5 years, respectively. Also, the specificity of the anti-xCT antibody was validated. Results: The expression level and prognostic significance of xCT were strongly dependent on tumor location. In oropharyngeal squamous cell carcinoma (OPSCC) patients, xCT expression was a significant prognostic factor for 5-year overall survival (OAS) (HR: 2.71; 95% CI 1.67-4.39; p < 0.001), disease-specific survival (DSS) (HR: 2.58; 95% CI 1.47-4.54; p = 0.001), and disease-free survival (DFS) (HR: 2.69; 95% CI 1.55-4.64; p < 0.001). Five-year survival rates for OPSCC patients with high and low levels of xCT were OAS 34% versus 62%; DSS 51% versus 73%; DFS 43% versus 73%, respectively. According to a multivariate model adjusted for age, T-class, nodal positivity, and tobacco consumption, xCT was an independent prognostic factor for 3-year survival, in which it outperformed p16 IHC. Similar associations were not observed in squamous cell carcinomas of oral cavity or larynx. Regarding treatment modalities, xCT was most predictive in HNSCC patients who received radiotherapy. Conclusions: High xCT expression was associated with poor prognosis in OPSCC. Our findings suggest that joint analysis of xCT and p16 may add significant value in OPSCC treatment stratification.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Laryngeal Papillary Squamous Cell Carcinoma: A Population-Based Analysis of Incidence and Survival
    Dutta, Rahul
    Husain, Qasim
    Kam, David
    Dubal, Pariket M.
    Baredes, Soly
    Eloy, Jean Anderson
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2015, 153 (01) : 54 - 59
  • [42] Head and neck squamous cell carcinoma
    不详
    Nature Reviews Disease Primers, 6 (1)
  • [43] Squamous cell carcinoma in the head and neck
    Al-Reefy, Hiba
    Dhar, Vikrain
    Dilkes, Mike
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2007, 68 (07) : 380 - 383
  • [44] HEAD AND NECK SQUAMOUS CELL CARCINOMA
    不详
    NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01):
  • [45] Squamous cell carcinoma of the head and neck
    Lorenz, K. J.
    Maier, H.
    HNO, 2008, 56 (04) : 402 - 409
  • [46] Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck
    Dirks, Nathanael L.
    Nolting, Arno
    Kovar, Andreas
    Meibohm, Bernd
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (03): : 267 - 278
  • [47] Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population
    Fernandez-Mateos, Javier
    Seijas-Tamayo, Raquel
    Adansa Klain, Juan Carlos
    Pastor Borgonon, Miguel
    Perez-Ruiz, Elisabeth
    Mesia, Card
    del Barco, Elvira
    Salvador Coloma, Carmen
    Rueda Dominguez, Antonio
    Caballero Daroqui, Javier
    Fernandez Ruiz, Encarnacion
    Ocana, Alberto
    Gonzalez-Sarmiento, Rogelio
    Jesus Cruz-Hernandez, Juan
    CANCERS, 2019, 11 (04)
  • [48] EGFR regulates the side population in head and neck squamous cell carcinoma
    Chen, JS
    Pardo, FS
    Wang-Rodriguez, J
    Chu, TS
    Lopez, JP
    Aguilera, J
    Altuna, X
    Weisman, RA
    Ongkeko, WM
    LARYNGOSCOPE, 2006, 116 (03): : 401 - 406
  • [49] Bladder transitional cell carcinoma anatomic primary site as a predictor of survival and mortality: a population-based retrospective cohort study
    Hemade, Ali
    Hallit, Souheil
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (10): : 5716 - 5723
  • [50] Subglottic squamous cell carcinoma in Denmark 1971-2015-a national population-based cohort study from DAHANCA, the Danish Head and Neck Cancer group
    Hill-Madsen, Louise
    Kristensen, Claus A.
    Andersen, Elo
    Johansen, Jorgen
    Andersen, Lisbeth J.
    Primdahl, Hanne
    Overgaard, Jens
    Lyhne, Nina M.
    ACTA ONCOLOGICA, 2019, 58 (10) : 1509 - 1513